Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: April 2011

Chapter 54 - Antiemetics

Related content

Powered by UNSILO

References

1. Scholz J, Steinfath M, Tonner PH. Postoperative nausea and vomiting. Curr Opin Anaesthesiol 1999; 12: 657–61.
2. Priebe HJ. Perioperative myocardial infarction: aetiology and prevention. Br J Anaesth 2005; 95: 3–19.
3. Scholz J, Steinfath M. Prophylaxis and therapy of postoperative nausea and vomiting. In: Herbert M, Holzer P, Roewer N, eds., Problems of the Gastrointestinal Tract in Anesthesia, the Perioperative Period, and Intensive Care. Berlin: Springer, 1999: 313–26.
4. Rose J, Watcha M. Postoperative nausea and vomiting. In: Benumof J, Saidman L, eds., Anesthesia and Perioperative Complications, 2nd edn. St Louis, MO: Mosby, 1999: 425–40.
5. Golembiewski J, Chernin E, Chopra T. Prevention and treatment of postoperative nausea and vomiting. Am J Health Syst Pharm 2005; 62: 1247–60.
6. Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350: 2441–51.
7. Silva AC, O'Ryan F, Poor DB. Postoperative nausea and vomiting (PONV) after orthognathic surgery: a retrospective study and literature review. J Oral Maxillofac Surg 2006; 64: 1385–97.
8. Simpson K, Lynch L. Physiology and pharmacology of nausea and vomiting. In: Hemmings HJ, Hopkins P, eds., Foundations of Anesthesia: Basic and Clinical Sciences, 2nd edn. St Louis, MO: Mosby, 2005: 623–30.
9. Kreis ME. Postoperative nausea and vomiting. Auton Neurosci 2006; 129: 86–91.
10. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007; 21: 813–33.
11. Gesztesi Z, Scuderi PE, White PF, et al. Substance P (neurokinin-1) antagonist prevents postoperative vomiting after abdominal hysterectomy procedures. Anesthesiology 2000; 93: 931–7.
12. Kranke P, Eberhart LH, Toker H, et al. A prospective evaluation of the POVOC score for the prediction of postoperative vomiting in children. Anesth Analg 2007; 105: 1592–7.
13. Tramer MR. [Prevention and treatment of postoperative nausea and vomiting in children: an evidence-based approach]. Ann Fr Anesth Reanim 2007; 26: 529–34.
14. Fujii Y. Prophylaxis of postoperative nausea and vomiting in patients scheduled for breast surgery. Clin Drug Investig 2006; 26: 427–37.
15. Fujii Y, Toyooka H, Tanaka H. Prevention of postoperative nausea and vomiting in female patients during menstruation: comparison of droperidol, metoclopramide and granisetron. Br J Anaesth 1998; 80: 248–9.
16. Kranke P, Apefel CC, Papenfuss T, et al. An increased body mass index is no risk factor for postoperative nausea and vomiting: a systematic review and results of original data. Acta Anaesthesiol Scand 2001; 45: 160–6.
17. Choi DH, Ko JS, Ahn HJ, Kim JA. A korean predictive model for postoperative nausea and vomiting. J Korean Med Sci 2005; 20: 811–15.
18. Pierre S, Corno G, Benais H, Apfel CC. A risk score-dependent antiemetic approach effectively reduces postoperative nausea and vomiting – a continuous quality improvement initiative. Can J Anaesth 2004; 51: 320–5.
19. Chen CC, Lin CS, Ko YP, et al. Premedication with mirtazapine reduces preoperative anxiety and postoperative nausea and vomiting. Anesth Analg 2008; 106: 109–13.
20. Brady M, Kinn S, O'Rourke K, Randhawa N, Stuart P. Preoperative fasting for preventing perioperative complications in children. Cochrane Database Syst Rev 2005; 4: CD005285.
21. Brady M, Kinn S, Stuart P. Preoperative fasting for adults to prevent perioperative complications. Cochrane Database Syst Rev 2003; 4: CD004423.
22. Scholz J, Hennes HJ, Steinfath M, et al. Tropisetron or ondansetron compared with placebo for prevention of postoperative nausea and vomiting. Eur J Anaesthesiol 1998; 15: 676–85.
23. Bolton CM, Myles PS, Carlin JB, Nolan T. Randomized, double-blind study comparing the efficacy of moderate-dose metoclopramide and ondansetron for the prophylactic control of postoperative vomiting in children after tonsillectomy. Br J Anaesth 2007; 99: 699–703.
24. Kovac AL. Management of postoperative nausea and vomiting in children. Paediatr Drugs 2007; 9: 47–69.
25. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102: 1884–98.
26. Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91: 693–700.
27. Tramer M, Moore A, McQuay H. Meta-analytic comparison of prophylactic antiemetic efficacy for postoperative nausea and vomiting: propofol anaesthesia vs omitting nitrous oxide vs total i.v. anaesthesia with propofol. Br J Anaesth 1997; 78: 256–9.
28. Myles PS, Leslie K, Chan MT, et al. Avoidance of nitrous oxide for patients undergoing major surgery: a randomized controlled trial. Anesthesiology 2007; 107: 221–31.
29. Myles PS, Leslie K, Silbert B, Paech MJ, Peyton P. A review of the risks and benefits of nitrous oxide in current anaesthetic practice. Anaesth Intensive Care 2004; 32: 165–72.
30. Sneyd JR, Carr A, Byrom WD, Bilski AJ. A meta-analysis of nausea and vomiting following maintenance of anaesthesia with propofol or inhalational agents. Eur J Anaesthesiol 1998; 15: 433–45.
31. Apfel CC, Kranke P, Katz MH, et al. Volatile anaesthetics may be the main cause of early but not delayed postoperative vomiting: a randomized controlled trial of factorial design. Br J Anaesth 2002; 88: 659–68.
32. Apfel CC, Stoecklein K, Lipfert P. PONV: a problem of inhalational anaesthesia? Best Pract Res Clin Anaesthesiol 2005; 19: 485–500.
33. Wallenborn J, Rudolph C, Gelbrich G, et al. The impact of isoflurane, desflurane, or sevoflurane on the frequency and severity of postoperative nausea and vomiting after lumbar disc surgery. J Clin Anesth 2007; 19: 180–5.
34. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology 2003; 98: 6–13.
35. Wappler F, Rossaint R, Baumert J, et al. Multicenter randomized comparison of xenon and isoflurane on left ventricular function in patients undergoing elective surgery. Anesthesiology 2007; 106: 463–71.
36. Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T. The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3 receptors expressed in Xenopus oocytes. Anesthesiology 2002; 96: 699–704.
37. Coburn M, Kunitz O, Apfel CC, et al. Incidence of postoperative nausea and emetic episodes after xenon anaesthesia compared with propofol-based anaesthesia. Br J Anaesth 2008; 100: 787–91.
38. Roberts GW, Bekker TB, Carlsen HH, et al. Postoperative nausea and vomiting are strongly influenced by postoperative opioid use in a dose-related manner. Anesth Analg 2005; 101: 1343–8.
39. Langevin S, Lessard MR, Trepanier CA, Baribault JP. Alfentanil causes less postoperative nausea and vomiting than equipotent doses of fentanyl or sufentanil in outpatients. Anesthesiology 1999; 91: 1666–73.
40. Rama-Maceiras P, Ferreira TA, Molins N, et al. Less postoperative nausea and vomiting after propofol + remifentanil versus propofol + fentanyl anaesthesia during plastic surgery. Acta Anaesthesiol Scand 2005; 49: 305–11.
41. Martorano PP, Aloj F, Baietta S, et al. Sufentanil-propofol vs remifentanil-propofol during total intravenous anesthesia for neurosurgery. A multicentre study. Minerva Anestesiol 2008; 74: 233–43.
42. Unkel W, Peters J. [Postoperative nausea and emesis: mechanisms and treatment]. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33: 533–44.
43. Tramer M, Moore A, McQuay H. Propofol anaesthesia and postoperative nausea and vomiting: quantitative systematic review of randomized controlled studies. Br J Anaesth 1997; 78: 247–55.
44. Tramer MR, Fuchs-Buder T. Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth 1999; 82: 379–86.
45. Chhibber AK, Lustik SJ, Thakur R, Francisco DR, Fickling KB. Effects of anticholinergics on postoperative vomiting, recovery, and hospital stay in children undergoing tonsillectomy with or without adenoidectomy. Anesthesiology 1999; 90: 697–700.
46. Cheng CR, Sessler DI, Apfel CC. Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting? Anesth Analg 2005; 101: 1349–55.
47. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg 2007; 104: 569–74.
48. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 2007; 101: 143–50.
49. Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007; 105: 1615–28.
50. Habib AS, Gan TJ. Evidence-based management of postoperative nausea and vomiting: a review. Can J Anaesth 2004; 51: 326–41.
51. Gan TJ, Meyer T, Apfel CC, et al. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003; 97: 62–71.
52. Kranke P, Morin AM, Roewer N, Eberhart LH. Dimenhydrinate for prophylaxis of postoperative nausea and vomiting: a meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand 2002; 46: 238–44.
53. Kranke P, Morin AM, Roewer N, Wulf H, Eberhart LH. The efficacy and safety of transdermal scopolamine for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2002; 95: 133–43.
54. Turner KE, Parlow JL, Avery ND, Tod DA, Day AG. Prophylaxis of postoperative nausea and vomiting with oral, long-acting dimenhydrinate in gynecologic outpatient laparoscopy. Anesth Analg 2004; 98: 1660–4.
55. Chan MT, Choi KC, Gin T, et al. The additive interactions between ondansetron and droperidol for preventing postoperative nausea and vomiting. Anesth Analg 2006; 103: 1155–62.
56. Jones S, Strobl R, Crosby D, et al. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron. AANA J 2006; 74: 127–32.
57. Diemunsch P, Apfel C, Gan TJ, et al. Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant. Curr Med Res Opin 2007; 23: 2559–65.
58. Diemunsch P, Gan TJ, Philip BK, et al. Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery. Br J Anaesth 2007; 99: 202–11.
59. Wallenborn J, Gelbrich G, Bulst D, et al. Prevention of postoperative nausea and vomiting by metoclopramide combined with dexamethasone: randomised double blind multicentre trial. BMJ 2006; 333: 324.
60. Leksowski K, Peryga P, Szyca R. Ondansetron, metoclopramid, dexamethason, and their combinations compared for the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: a prospective randomized study. Surg Endosc 2006; 20: 878–82.
61. Henzi I, Walder B, Tramer MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized, placebo-controlled studies. Br J Anaesth 1999; 83: 761–71.
62. McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol: a review of its use in the management of postoperative nausea and vomiting. Drugs 2006; 66: 2123–47.
63. Culebras X, Corpataux JB, Gaggero G, Tramer MR. The antiemetic efficacy of droperidol added to morphine patient-controlled analgesia: a randomized, controlled, multicenter dose-finding study. Anesth Analg 2003; 97: 816–21.
64. Henzi I, Sonderegger J, Tramer MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anaesth 2000; 47: 537–51.
65. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005; 102: 1101–5.
66. Charbit B, Albaladejo P, Funck-Brentano C, et al. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005; 102: 1094–100.
67. Gan TJ. Postoperative nausea and vomiting – can it be eliminated? JAMA 2002; 287: 1233–6.
68. So PC. Neuroleptic malignant syndrome induced by droperidol. Hong Kong Med J 2001; 7: 101–3.
69. Edgar J. Droperidol-induced neuroleptic malignant syndrome. Hosp Med 1999; 60: 448–9.
70. Habib AS, Gan TJ. Food and drug administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg 2003; 96: 1377–9.
71. Leslie JB, Gan TJ. Meta-analysis of the safety of 5-HT3 antagonists with dexamethasone or droperidol for prevention of PONV. Ann Pharmacother 2006; 40: 856–72.
72. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007; 107: 531–6.
73. Charbit B, Funck-Brentano C. Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology 2007; 107: 524–6.
74. Laer S, Scholz J, Ritterbach C, et al. Association between increased 5-HIAA plasma concentrations and postoperative nausea and vomiting in patients undergoing general anaesthesia for surgery. Eur J Anaesthesiol 2001; 18: 833–5.
75. Meneses A. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Rev Neurosci 1998; 9: 275–89.
76. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol Suppl 2000; 113: 37–45.
77. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007; 11: 527–40.
78. Davies PA, Pistis M, Hanna MC, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397: 359–63.
79. Brady CA, Dover TJ, Massoura AN, et al. Identification of 5-HT3A and 5-HT3B receptor subunits in human hippocampus. Neuropharmacology 2007; 52: 1284–90.
80. Niesler B, Walstab J, Combrink S, et al. Characterization of the novel human serotonin receptor subunits 5-HT3C,5-HT3D, and 5-HT3E. Mol Pharmacol 2007; 72: 8–17.
81. Stewart A, Davies PA, Kirkness EF, Safa P, Hales TG. Introduction of the 5-HT3B subunit alters the functional properties of 5-HT3 receptors native to neuroblastoma cells. Neuropharmacology 2003; 44: 214–23.
82. Niesler B, Frank B, Kapeller J, Rappold GA. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310: 101–11.
83. Neufeld SM, Newburn-Cook CV. The efficacy of 5-HT3 receptor antagonists for the prevention of postoperative nausea and vomiting after craniotomy: a meta-analysis. J Neurosurg Anesthesiol 2007; 19: 10–17.
84. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006; 19: 606–11.
85. Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; 3: CD004125.
86. Somers GI, Harris AJ, Bayliss MK, Houston JB. The metabolism of the 5HT3 antagonists ondansetron, dolasetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes. Xenobiotica 2007; 37: 832–54.
87. Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998; 86: 274–82.
88. Kuryshev YA, Brown AM, Wang L, Benedict CR, Rampe D. Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. J Pharmacol Exp Ther 2000; 295: 614–20.
89. Gan TJ. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs 2005; 19: 225–38.
90. Moussa AA, Oregan PJ. Prevention of postoperative nausea and vomiting in patients undergoing laparoscopic bariatric surgery–granisetron alone vs granisetron combined with dexamethasone/droperidol. Middle East J Anesthesiol 2007; 19: 357–67.
91. Fujii Y, Saitoh Y, Tanaka H, Toyooka H. Granisetron/dexamethasone combination for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Eur J Anaesthesiol 2000; 17: 64–8.
92. Apfel CC, Kranke P, Piper S, et al. [Nausea and vomiting in the postoperative phase. Expert- and evidence-based recommendations for prophylaxis and therapy]. Anaesthesist 2007; 56: 1170–80.
93. Rubenstein EB, Slusher BS, Rojas C, Navari RM. New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 2006; 12: 341–7.
94. Apfel CC, Cakmakkaya OS, Frings G, et al. Droperidol has comparable clinical efficacy against both nausea and vomiting. Br J Anaesth 2009; 103: 359–63.
95. Jokela R, Kranke P, Danzeisen O, et al. Ondansetron has similar clinical efficacy against both nausea and vomiting. Anaesthesia 2009; 64: 147–51.
96. Apfel CC, Malhotra A, Leslie JB. The role of neurokinin-1 receptor antagonists for the management of postoperative nausea and vomiting. Curr Opin Anaesthesiol 2008; 21: 427–32.
97. Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104: 1082–9.
98. Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology 2010; 113: 74–82.
99. Warren A, King L. A review of the efficacy of dexamethasone in the prevention of postoperative nausea and vomiting. J Clin Nurs 2008; 17: 58–68.
100. Henzi I, Walder B, Tramer MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth Analg 2000; 90: 186–94.
101. Wang JJ, Ho ST, Lee SC, Liu YC, Ho CM. The use of dexamethasone for preventing postoperative nausea and vomiting in females undergoing thyroidectomy: a dose-ranging study. Anesth Analg 2000; 91: 1404–7.
102. Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic antiemetic for postoperative nausea and vomiting. Anesth Analg 2000; 91: 136–9.
103. Gan TJ, Coop A, Philip BK. A randomized, double-blind study of granisetron plus dexamethasone versus ondansetron plus dexamethasone to prevent postoperative nausea and vomiting in patients undergoing abdominal hysterectomy. Anesth Analg 2005; 101: 1323–9.
104. Fujii Y, Nakayama M. Dexamethasone for reduction of nausea, vomiting and analgesic use after gynecological laparoscopic surgery. Int J Gynaecol Obstet 2008; 100: 27–30.
105. Paech MJ, Rucklidge MW, Lain J, et al. Ondansetron and dexamethasone dose combinations for prophylaxis against postoperative nausea and vomiting. Anesth Analg 2007; 104: 808–14.
106. Rusch D, Arndt C, Martin H, Kranke P. The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting. Anaesthesia 2007; 62: 810–17.
107. Bauer KP, Dom PM, Ramirez AM, O'Flaherty JE. Preoperative intravenous midazolam: benefits beyond anxiolysis. J Clin Anesth 2004; 16: 177–83.
108. Lee Y, Wang JJ, Yang YL, Chen A, Lai HY. Midazolam vs ondansetron for preventing postoperative nausea and vomiting: a randomised controlled trial. Anaesthesia 2007; 62: 18–22.
109. Oddby-Muhrbeck E, Eksborg S, Bergendahl HT, Muhrbeck O, Lonnqvist PA. Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. Anesthesiology 2002; 96: 1109–14.
110. Watcha MF, Simeon RM, White PF, Stevens JL. Effect of propofol on the incidence of postoperative vomiting after strabismus surgery in pediatric outpatients. Anesthesiology 1991; 75: 204–9.
111. Visser K, Hassink EA, Bonsel GJ, Moen J, Kalkman CJ. Randomized controlled trial of total intravenous anesthesia with propofol versus inhalation anesthesia with isoflurane-nitrous oxide: postoperative nausea with vomiting and economic analysis. Anesthesiology 2001; 95: 616–26.
112. Cechetto DF, Diab T, Gibson CJ, Gelb AW. The effects of propofol in the area postrema of rats. Anesth Analg 2001; 92: 934–42.
113. Tramer MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions, and methodological issues. Acta Anaesthesiol Scand 2001; 45: 4–13.
114. Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52: 443–9.
115. Junger A, Michel A, Benson M, et al. Evaluation of the suitability of a patient data management system for ICUs on a general ward. Int J Med Inform 2001; 64: 57–66.
116. Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91: 109–18.
117. Apfel CC, Kranke P, Eberhart LH, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88: 234–40.
118. van den Bosch JE, Kalkman CJ, Vergouwe Y, et al. Assessing the applicability of scoring systems for predicting postoperative nausea and vomiting. Anaesthesia 2005; 60: 323–31.
119. Eberhart LH, Geldner G, Kranke P, et al. The development and validation of a risk score to predict the probability of postoperative vomiting in pediatric patients. Anesth Analg 2004; 99: 1630–7.
120. Eberhart LH, Morin AM, Guber D, et al. Applicability of risk scores for postoperative nausea and vomiting in adults to paediatric patients. Br J Anaesth 2004; 93: 386–92.
121. Apfel CC, Korttila K, Abdalla M, et al. An international multicenter protocol to assess the single and combined benefits of antiemetic interventions in a controlled clinical trial of a 2×2×2×2×2×2 factorial design (IMPACT). Control Clin Trials 2003; 24: 736–51.
122. Habib AS, White WD, Eubanks S, Pappas TN, Gan TJ. A randomized comparison of a multimodal management strategy versus combination antiemetics for the prevention of postoperative nausea and vomiting. Anesth Analg 2004; 99: 77–81.